PMID- 28657833
OWN - NLM
STAT- MEDLINE
DCOM- 20180705
LR  - 20181202
IS  - 1439-7609 (Electronic)
IS  - 1439-7595 (Linking)
VI  - 28
IP  - 1
DP  - 2018 Jan
TI  - Serum interleukin-6 and survivin levels predict clinical response to etanercept 
      treatment in patients with established rheumatoid arthritis.
PG  - 126-132
LID - 10.1080/14397595.2017.1317384 [doi]
AB  - OBJECTIVES: To investigate the correlation of nine potential biomarkers with 
      clinical response to etanercept (ETN) therapy in establish rheumatoid arthritis 
      (RA) patients. METHODS: Seventy-three patients with established RA were enrolled 
      in the prospective cohort study. Sixty-nine of 73 cases were included into final 
      analysis for response after 24-week ETN therapy. Serum expression of nine studied 
      proteins was measured by enzyme-linked immunosorbent assay (ELISA). Tumor 
      necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), IL-6, IL-17A, IL-21, IL-34, 
      RANKL, survivin, and COMP were selected as candidate biomarkers. RESULTS: Serum 
      IL-6 level was increased in responders than in nonresponders at baseline, 
      p = .034; to the contrary, serum survivin level was decreased in responders, 
      p = .009. Receiver operating characteristic (ROC) curve illuminated the 
      combination of IL-6 and survivin expressions could predict clinical response with 
      a high AUC 0.875, 95% CI: 0.771-0.976. Furthermore, we found the combination of 
      IL-6 high expression and survivin low expression increased the responding 
      possibility to nearly 20-fold (OR 19.687, 95% CI: 4.087-94.839, p < .001) 
      compared to IL-6 low or survivin high expression by univariate analysis. However, 
      only survivin low expression (p = .002) and CRP (p = .014) high expression were 
      independent predictive factors for achieving clinical response, while IL-6 lack 
      independent predictive value (p = .267). CONCLUSIONS: Comprehensive measurement 
      of IL-6 and survivin in serum could be served as a convincing biomarker for 
      clinical response in ETN-treated patients with established RA.
FAU - Shi, Rui
AU  - Shi R
AD  - a Department of Rheumatology and Immunology , Xinjiang Uygur Autonomous Region 
      Hospital of Traditional Chinese Medicine , Xinjiang , China.
FAU - Chen, Muzhi
AU  - Chen M
AD  - a Department of Rheumatology and Immunology , Xinjiang Uygur Autonomous Region 
      Hospital of Traditional Chinese Medicine , Xinjiang , China.
FAU - Litifu, Bahaerguli
AU  - Litifu B
AD  - a Department of Rheumatology and Immunology , Xinjiang Uygur Autonomous Region 
      Hospital of Traditional Chinese Medicine , Xinjiang , China.
LA  - eng
PT  - Journal Article
DEP - 20170628
PL  - England
TA  - Mod Rheumatol
JT  - Modern rheumatology
JID - 100959226
RN  - 0 (Antirheumatic Agents)
RN  - 0 (BIRC5 protein, human)
RN  - 0 (Biomarkers)
RN  - 0 (Inhibitor of Apoptosis Proteins)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Interleukin-6)
RN  - 0 (Survivin)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - OP401G7OJC (Etanercept)
SB  - IM
CIN - Mod Rheumatol. 2018 Mar;28(2):380. PMID: 29067845
MH  - Adult
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/blood/*drug therapy
MH  - Biomarkers/blood
MH  - Etanercept/*therapeutic use
MH  - Female
MH  - Humans
MH  - Inhibitor of Apoptosis Proteins/*blood
MH  - Interleukin-1beta/blood
MH  - Interleukin-6/*blood
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Survivin
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/blood
OTO - NOTNLM
OT  - Etanercept
OT  - interleukin-6
OT  - predict
OT  - response
OT  - survivin
EDAT- 2017/06/29 06:00
MHDA- 2018/07/06 06:00
CRDT- 2017/06/29 06:00
PHST- 2017/06/29 06:00 [pubmed]
PHST- 2018/07/06 06:00 [medline]
PHST- 2017/06/29 06:00 [entrez]
AID - 10.1080/14397595.2017.1317384 [doi]
PST - ppublish
SO  - Mod Rheumatol. 2018 Jan;28(1):126-132. doi: 10.1080/14397595.2017.1317384. Epub 
      2017 Jun 28.